Indication-specific dosing for he shou wu, polygonum multiflorum (fo-ti), frequency-based adverse effects, comprehensive interactions, contraindications, pregnancy & lactation schedules, and cost information.

Sections

Sections Fo-ti
Suggested Dosing
Suggested Uses
Interactions
Adverse Effects
Warnings
Pregnancy
Pharmacology

Suggested Dosing

Check Mfr instruction

raw herb: 9-15 g

Suggested Uses

Adaptogen, constipation, anti-aging

Interaction Checker

Enter a drug name and Fo-ti

No Results

No Interactions Found

Interactions Found

Contraindicated

Serious - Use Alternative

Significant - Monitor Closely

Minor

All Interactions Sort By:

Contraindicated (0)

Serious - Use Alternative (0)

Monitor Closely (0)

Minor (44)

acarbose
fo-ti increases effects of acarbose by pharmacodynamic synergism. Minor/Significance Unknown.
amlodipine
fo-ti increases effects of amlodipine by pharmacodynamic synergism. Minor/Significance Unknown.
bendroflumethiazide
fo-ti increases effects of bendroflumethiazide by pharmacodynamic synergism. Minor/Significance Unknown. Risk of hypokalemia (theoretical).
bumetanide
fo-ti increases effects of bumetanide by pharmacodynamic synergism. Minor/Significance Unknown. Risk of hypokalemia (theoretical).
chlorothiazide
fo-ti increases effects of chlorothiazide by pharmacodynamic synergism. Minor/Significance Unknown. Risk of hypokalemia (theoretical).
chlorpropamide
fo-ti increases effects of chlorpropamide by pharmacodynamic synergism. Minor/Significance Unknown.
chlorthalidone
fo-ti increases effects of chlorthalidone by pharmacodynamic synergism. Minor/Significance Unknown. Risk of hypokalemia (theoretical).
clevidipine
fo-ti increases effects of clevidipine by pharmacodynamic synergism. Minor/Significance Unknown.
cyclopenthiazide
fo-ti increases effects of cyclopenthiazide by pharmacodynamic synergism. Minor/Significance Unknown. Risk of hypokalemia (theoretical).
diltiazem
fo-ti increases effects of diltiazem by pharmacodynamic synergism. Minor/Significance Unknown.
ethacrynic acid
fo-ti increases effects of ethacrynic acid by pharmacodynamic synergism. Minor/Significance Unknown. Risk of hypokalemia (theoretical).
felodipine
fo-ti increases effects of felodipine by pharmacodynamic synergism. Minor/Significance Unknown.
furosemide
fo-ti increases effects of furosemide by pharmacodynamic synergism. Minor/Significance Unknown. Risk of hypokalemia (theoretical).
glimepiride
fo-ti increases effects of glimepiride by pharmacodynamic synergism. Minor/Significance Unknown.
glipizide
fo-ti increases effects of glipizide by pharmacodynamic synergism. Minor/Significance Unknown.
glyburide
fo-ti increases effects of glyburide by pharmacodynamic synergism. Minor/Significance Unknown.
hydrochlorothiazide
fo-ti increases effects of hydrochlorothiazide by pharmacodynamic synergism. Minor/Significance Unknown. Risk of hypokalemia (theoretical).
indapamide
fo-ti increases effects of indapamide by pharmacodynamic synergism. Minor/Significance Unknown. Risk of hypokalemia (theoretical).
insulin aspart
fo-ti increases effects of insulin aspart by pharmacodynamic synergism. Minor/Significance Unknown.
insulin detemir
fo-ti increases effects of insulin detemir by pharmacodynamic synergism. Minor/Significance Unknown.
insulin glargine
fo-ti increases effects of insulin glargine by pharmacodynamic synergism. Minor/Significance Unknown.
insulin glulisine
fo-ti increases effects of insulin glulisine by pharmacodynamic synergism. Minor/Significance Unknown.
insulin lispro
fo-ti increases effects of insulin lispro by pharmacodynamic synergism. Minor/Significance Unknown.
insulin NPH
fo-ti increases effects of insulin NPH by pharmacodynamic synergism. Minor/Significance Unknown.
insulin regular human
fo-ti increases effects of insulin regular human by pharmacodynamic synergism. Minor/Significance Unknown.
isradipine
fo-ti increases effects of isradipine by pharmacodynamic synergism. Minor/Significance Unknown.
metformin
fo-ti increases effects of metformin by pharmacodynamic synergism. Minor/Significance Unknown.
methyclothiazide
fo-ti increases effects of methyclothiazide by pharmacodynamic synergism. Minor/Significance Unknown. Risk of hypokalemia (theoretical).
metolazone
fo-ti increases effects of metolazone by pharmacodynamic synergism. Minor/Significance Unknown. Risk of hypokalemia (theoretical).
miglitol
fo-ti increases effects of miglitol by pharmacodynamic synergism. Minor/Significance Unknown.
nateglinide
fo-ti increases effects of nateglinide by pharmacodynamic synergism. Minor/Significance Unknown.
nicardipine
fo-ti increases effects of nicardipine by pharmacodynamic synergism. Minor/Significance Unknown.
nifedipine
fo-ti increases effects of nifedipine by pharmacodynamic synergism. Minor/Significance Unknown.
nisoldipine
fo-ti increases effects of nisoldipine by pharmacodynamic synergism. Minor/Significance Unknown.
pioglitazone
fo-ti increases effects of pioglitazone by pharmacodynamic synergism. Minor/Significance Unknown.
repaglinide
fo-ti increases effects of repaglinide by pharmacodynamic synergism. Minor/Significance Unknown.
rosiglitazone
fo-ti increases effects of rosiglitazone by pharmacodynamic synergism. Minor/Significance Unknown.
saxagliptin
fo-ti increases effects of saxagliptin by pharmacodynamic synergism. Minor/Significance Unknown.
sitagliptin
fo-ti increases effects of sitagliptin by pharmacodynamic synergism. Minor/Significance Unknown.
tolazamide
fo-ti increases effects of tolazamide by pharmacodynamic synergism. Minor/Significance Unknown.
tolbutamide
fo-ti increases effects of tolbutamide by pharmacodynamic synergism. Minor/Significance Unknown.
torsemide
fo-ti increases effects of torsemide by pharmacodynamic synergism. Minor/Significance Unknown. Risk of hypokalemia (theoretical).
verapamil
fo-ti increases effects of verapamil by pharmacodynamic synergism. Minor/Significance Unknown.
vildagliptin
fo-ti increases effects of vildagliptin by pharmacodynamic synergism. Minor/Significance Unknown.

acarbose
Minor (1)fo-ti increases effects of acarbose by pharmacodynamic synergism. Minor/Significance Unknown.
amlodipine
Minor (1)fo-ti increases effects of amlodipine by pharmacodynamic synergism. Minor/Significance Unknown.
bendroflumethiazide
Minor (1)fo-ti increases effects of bendroflumethiazide by pharmacodynamic synergism. Minor/Significance Unknown. Risk of hypokalemia (theoretical).
bumetanide
Minor (1)fo-ti increases effects of bumetanide by pharmacodynamic synergism. Minor/Significance Unknown. Risk of hypokalemia (theoretical).
chlorothiazide
Minor (1)fo-ti increases effects of chlorothiazide by pharmacodynamic synergism. Minor/Significance Unknown. Risk of hypokalemia (theoretical).
chlorpropamide
Minor (1)fo-ti increases effects of chlorpropamide by pharmacodynamic synergism. Minor/Significance Unknown.
chlorthalidone
Minor (1)fo-ti increases effects of chlorthalidone by pharmacodynamic synergism. Minor/Significance Unknown. Risk of hypokalemia (theoretical).
clevidipine
Minor (1)fo-ti increases effects of clevidipine by pharmacodynamic synergism. Minor/Significance Unknown.
cyclopenthiazide
Minor (1)fo-ti increases effects of cyclopenthiazide by pharmacodynamic synergism. Minor/Significance Unknown. Risk of hypokalemia (theoretical).
diltiazem
Minor (1)fo-ti increases effects of diltiazem by pharmacodynamic synergism. Minor/Significance Unknown.
ethacrynic acid
Minor (1)fo-ti increases effects of ethacrynic acid by pharmacodynamic synergism. Minor/Significance Unknown. Risk of hypokalemia (theoretical).
felodipine
Minor (1)fo-ti increases effects of felodipine by pharmacodynamic synergism. Minor/Significance Unknown.
furosemide
Minor (1)fo-ti increases effects of furosemide by pharmacodynamic synergism. Minor/Significance Unknown. Risk of hypokalemia (theoretical).
glimepiride
Minor (1)fo-ti increases effects of glimepiride by pharmacodynamic synergism. Minor/Significance Unknown.
glipizide
Minor (1)fo-ti increases effects of glipizide by pharmacodynamic synergism. Minor/Significance Unknown.
glyburide
Minor (1)fo-ti increases effects of glyburide by pharmacodynamic synergism. Minor/Significance Unknown.
hydrochlorothiazide
Minor (1)fo-ti increases effects of hydrochlorothiazide by pharmacodynamic synergism. Minor/Significance Unknown. Risk of hypokalemia (theoretical).
indapamide
Minor (1)fo-ti increases effects of indapamide by pharmacodynamic synergism. Minor/Significance Unknown. Risk of hypokalemia (theoretical).
insulin aspart
Minor (1)fo-ti increases effects of insulin aspart by pharmacodynamic synergism. Minor/Significance Unknown.
insulin detemir
Minor (1)fo-ti increases effects of insulin detemir by pharmacodynamic synergism. Minor/Significance Unknown.
insulin glargine
Minor (1)fo-ti increases effects of insulin glargine by pharmacodynamic synergism. Minor/Significance Unknown.
insulin glulisine
Minor (1)fo-ti increases effects of insulin glulisine by pharmacodynamic synergism. Minor/Significance Unknown.
insulin lispro
Minor (1)fo-ti increases effects of insulin lispro by pharmacodynamic synergism. Minor/Significance Unknown.
insulin NPH
Minor (1)fo-ti increases effects of insulin NPH by pharmacodynamic synergism. Minor/Significance Unknown.
insulin regular human
Minor (1)fo-ti increases effects of insulin regular human by pharmacodynamic synergism. Minor/Significance Unknown.
isradipine
Minor (1)fo-ti increases effects of isradipine by pharmacodynamic synergism. Minor/Significance Unknown.
metformin
Minor (1)fo-ti increases effects of metformin by pharmacodynamic synergism. Minor/Significance Unknown.
methyclothiazide
Minor (1)fo-ti increases effects of methyclothiazide by pharmacodynamic synergism. Minor/Significance Unknown. Risk of hypokalemia (theoretical).
metolazone
Minor (1)fo-ti increases effects of metolazone by pharmacodynamic synergism. Minor/Significance Unknown. Risk of hypokalemia (theoretical).
miglitol
Minor (1)fo-ti increases effects of miglitol by pharmacodynamic synergism. Minor/Significance Unknown.
nateglinide
Minor (1)fo-ti increases effects of nateglinide by pharmacodynamic synergism. Minor/Significance Unknown.
nicardipine
Minor (1)fo-ti increases effects of nicardipine by pharmacodynamic synergism. Minor/Significance Unknown.
nifedipine
Minor (1)fo-ti increases effects of nifedipine by pharmacodynamic synergism. Minor/Significance Unknown.
nisoldipine
Minor (1)fo-ti increases effects of nisoldipine by pharmacodynamic synergism. Minor/Significance Unknown.
pioglitazone
Minor (1)fo-ti increases effects of pioglitazone by pharmacodynamic synergism. Minor/Significance Unknown.
repaglinide
Minor (1)fo-ti increases effects of repaglinide by pharmacodynamic synergism. Minor/Significance Unknown.
rosiglitazone
Minor (1)fo-ti increases effects of rosiglitazone by pharmacodynamic synergism. Minor/Significance Unknown.
saxagliptin
Minor (1)fo-ti increases effects of saxagliptin by pharmacodynamic synergism. Minor/Significance Unknown.
sitagliptin
Minor (1)fo-ti increases effects of sitagliptin by pharmacodynamic synergism. Minor/Significance Unknown.
tolazamide
Minor (1)fo-ti increases effects of tolazamide by pharmacodynamic synergism. Minor/Significance Unknown.
tolbutamide
Minor (1)fo-ti increases effects of tolbutamide by pharmacodynamic synergism. Minor/Significance Unknown.
torsemide
Minor (1)fo-ti increases effects of torsemide by pharmacodynamic synergism. Minor/Significance Unknown. Risk of hypokalemia (theoretical).
verapamil
Minor (1)fo-ti increases effects of verapamil by pharmacodynamic synergism. Minor/Significance Unknown.
vildagliptin
Minor (1)fo-ti increases effects of vildagliptin by pharmacodynamic synergism. Minor/Significance Unknown.

Adverse Effects

Diarrhea

Cautions

May cause diarrhea

Large doses can cause paresthesia

Pregnancy & Lactation

Pregnancy Category: N/A

Lactation: N/A

Pregnancy Categories

A: Generally acceptable. Controlled studies in pregnant women show no evidence of fetal risk.

B: May be acceptable. Either animal studies show no risk but human studies not available or animal studies showed minor risks and human studies done and showed no risk.

C: Use with caution if benefits outweigh risks. Animal studies show risk and human studies not available or neither animal nor human studies done.

D: Use in LIFE-THREATENING emergencies when no safer drug available. Positive evidence of human fetal risk.

X: Do not use in pregnancy. Risks involved outweigh potential benefits. Safer alternatives exist.

NA: Information not available.

Pharmacology

Metabolism: N/A

Excretion: N/A

Mechanism of Action

Unknown

Medscape prescription drug monographs are based on FDA-approved labeling information, unless otherwise noted, combined with additional data derived from primary medical literature.

[CLOSE WINDOW]

Sections Fo-ti
Suggested Dosing
Suggested Uses
Interactions
Adverse Effects
Warnings
Pregnancy
Pharmacology

Fo-ti (Herb/Suppl)